Advertising
Showing 1 to 15 of 190 entries
BUY on WEAKNESS
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
biotechnology / pharmaceutical
SELL
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
biotechnology / pharmaceutical
DON'T BUY
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
biotechnology / pharmaceutical
SELL
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
biotechnology / pharmaceutical
DON'T BUY
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
biotechnology / pharmaceutical
DON'T BUY
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
biotechnology / pharmaceutical
WAIT
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
biotechnology / pharmaceutical
DON'T BUY
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
biotechnology / pharmaceutical
SELL
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
biotechnology / pharmaceutical
DON'T BUY
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
biotechnology / pharmaceutical
DON'T BUY
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
biotechnology / pharmaceutical
WEAK BUY
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
biotechnology / pharmaceutical
DON'T BUY
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
biotechnology / pharmaceutical
DON'T BUY
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
biotechnology / pharmaceutical
WAIT
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
biotechnology / pharmaceutical
Showing 1 to 15 of 190 entries

Novelion(NVLN-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Novelion is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novelion(NVLN-T) Frequently Asked Questions

What is Novelion stock symbol?

Novelion is a OTC stock, trading under the symbol NVLN-T on the (). It is usually referred to as or NVLN-T

Is Novelion a buy or a sell?

In the last year, there was no coverage of Novelion published on Stockchase.

Is Novelion a good investment or a top pick?

Novelion was recommended as a Top Pick by on . Read the latest stock experts ratings for Novelion.

Why is Novelion stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novelion worth watching?

0 stock analysts on Stockchase covered Novelion In the last year. It is a trending stock that is worth watching.

What is Novelion stock price?

On , Novelion (NVLN-T) stock closed at a price of $.